Anzeige
Mehr »
Sonntag, 10.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41BEM | ISIN: US74907L4095 | Ticker-Symbol: 2EB0
Frankfurt
08.08.25 | 21:40
5,920 Euro
+2,78 % +0,160
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
QUOIN PHARMACEUTICALS LTD ADR Chart 1 Jahr
5-Tage-Chart
QUOIN PHARMACEUTICALS LTD ADR 5-Tage-Chart

Aktuelle News zur QUOIN PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoQuoin Pharmaceuticals, Ltd. - 10-Q, Quarterly Report-
QUOIN PHARMACEUTICALS Aktie jetzt für 0€ handeln
DoQuoin Pharmaceuticals, Ltd. - 8-K, Current Report-
31.07.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 20251
29.07.Positive Studiendaten beflügeln Aktie von Quoin Pharmaceuticals13
29.07.Quoin Pharmaceuticals stock rises after positive clinical updates1
29.07.Quoin Pharmaceuticals advances rare disease pipeline with two active trials2
29.07.Quoin picks its cornerstone, shelving 2 assets to build around lead program3
29.07.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Product Portfolio Update412Lead Product, QRX003, Being Tested in Two Active Registrational Clinical Studies for Netherton Syndrome Across the U.S., Europe, and the Middle East. QRX003 Peeling Skin Syndrome Clinical Program...
► Artikel lesen
08.07.Quoin Pharmaceuticals: Finanzvorstand Gordon Dunn scheidet aus1
08.07.Quoin Pharmaceuticals, Ltd. - 8-K, Current Report2
26.06.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases2
20.06.Quoin Pharmaceuticals, Ltd. - 8-K, Current Report1
04.06.Quoin Pharmaceuticals, Ltd. - 8-K, Current Report1
22.05.Quoin Gets FDA Nod For Second Pivotal Study Of QRX003 In Netherton Syndrome Patients1
22.05.FDA clears Quoin's new Netherton syndrome study2
22.05.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study173Study CL-QRX003-002 will test whole-body application of QRX003 in conjunction with off-label systemic therapy in approximately 12-15 subjects.Study CL-QRX003-002 complements first whole-body pivotal...
► Artikel lesen
20.05.Quoin Pharma Gets Orphan Drug Status In Europe For QRX003 In Netherton Syndrome1
20.05.Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome120Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone provides 10 years of market exclusivity in Europe upon approval ASHBURN, Va....
► Artikel lesen
14.05.Quoin Pharmaceuticals, Ltd. - 8-K, Current Report1
14.05.Why Quoin Pharmaceuticals (QNRX) Stock Is Exploding Higher Wednesday1
Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1